GlassScriptPhysician profile
Kelly M Devoogd
NPI 1780810192
$1,543.12
in general payments reported to CMS, 2019-2025
30 companies · $363 in 2025
The $363 reported for 2025 was more than what a typical Obstetrics provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $477 · 2020: $229 · 2021: $16.23 · 2022: $31.45 · 2023: $202 · 2024: $225 · 2025: $363.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $790.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $789.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $373.74 | 2023-2025 | |
| Amag Pharmaceuticals, INC. | $143.46 | 2019 | |
| Amgen INC. | $131.15 | 2020 | |
| Abbvie INC. | $97.79 | 2019-2025 | |
| Duchesnay USA Incorporated | $60.24 | 2019 | |
| Therapeuticsmd, INC. | $59.62 | 2019-2020 | |
| Daiichi Sankyo INC. | $58.35 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $52.95 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $44.64 | 2019-2021 | |
| Organon LLC | $42.55 | 2023-2025 | Nexplanon |
| Exeltis, USA INC. | $41.56 | 2019-2023 | Slynd |
| Pfizer INC. | $40.25 | 2023 | |
| Glaxosmithkline, LLC. | $35.83 | 2024-2025 | Bexsero, Arexvy, Shingrix |
| Corcept Therapeutics | $35.13 | 2025 | Korlym |
| Novo Nordisk INC | $34.09 | 2020-2025 | Wegovy |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $33.34 | 2025 | Mounjaro |
| Hologic Sales and Service, LLC | $31.14 | 2024 | Aptima, Thinprep 2000 Processor |
| Exact Sciences Corporation | $30.43 | 2025 | Cologuard Collection Kit |
| Lundbeck LLC | $22.02 | 2025 | Rexulti |
| Axsome Therapeutics, INC. | $20.50 | 2025 | Auvelity |
| Agile Therapeutics, INC. | $19.56 | 2022 | |
| Roche Diagnostics Corporation | $19.41 | 2019 | |
| Dexcom, INC. | $18.94 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.47 | 2025 | Caplyta |
| Mission Pharmacal Company | $15.43 | 2019 | |
| Currax Pharmaceuticals LLC | $14.73 | 2020 | |
| Vivus LLC | $13.50 | 2019 | |
| Astellas Pharma US INC | $11.89 | 2022 | |
| Vertical Pharmaceuticals, LLC | $11.77 | 2020 | |
| Nalpropion Pharmaceuticals LLC | $11.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelly Devoogd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.